Cargando…

Prostate cancer patients can benefit from 5-alpha-reductase inhibitor treatment: a meta-analysis

BACKGROUND: The efficacy and safety of 5α-reductase inhibitors (5ARIs) in treating prostate cancer (PCa) have not been fully determined. We performed a meta-analysis to evaluate the effectiveness and safety of 5ARIs for PCa patients. METHODS: A comprehensive literature search of online databases was...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Tuo, Lin, Xueming, Duan, Xiaolu, He, Zihao, Zhao, Zhijian, Zeng, Guohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271889/
https://www.ncbi.nlm.nih.gov/pubmed/32547884
http://dx.doi.org/10.7717/peerj.9282
_version_ 1783542157920960512
author Deng, Tuo
Lin, Xueming
Duan, Xiaolu
He, Zihao
Zhao, Zhijian
Zeng, Guohua
author_facet Deng, Tuo
Lin, Xueming
Duan, Xiaolu
He, Zihao
Zhao, Zhijian
Zeng, Guohua
author_sort Deng, Tuo
collection PubMed
description BACKGROUND: The efficacy and safety of 5α-reductase inhibitors (5ARIs) in treating prostate cancer (PCa) have not been fully determined. We performed a meta-analysis to evaluate the effectiveness and safety of 5ARIs for PCa patients. METHODS: A comprehensive literature search of online databases was conducted to obtain comparative studies exploring the effectiveness and safety of 5ARIs in treating PCa up to October 2019. Summarized odds ratio s (OR s) or hazard ratio s (HR s) were calculated to compare the outcomes between 5ARI and control groups. Our meta-analysis was registered in PROSPERO under number CRD42018109809. RESULTS: A total of 2,277 patients from 10 studies were included. No significant difference was found in prostate-specific antigen progression between two groups (OR = 0.82, 95% CI [0.52–1.29], P = 0.40). However, 5ARI treatment significantly reduced the total progression of PCa (OR = 0.61, 95% CI [0.48–0.77], P < 0.0001), especially for patients with local (OR = 0.56, 95% CI [0.44–0.73], P < 0.00001) and low-Gleason score (≤7) PCa (OR = 0.63, 95% CI [0.48–0.84], P = 0.002). Additionally, 5ARIs also significantly prolonged the progression-free survival time (HR = 0.57, 95% CI [0.34–0.96], P = 0.04) for PCa patients. No significant difference was found in the occurrence of PCa recurrence, metastasis, biopsy reclassification, and side-effects between two groups. CONCLUSIONS: Our study suggests that 5ARI treatment can benefit patients with local and low Gleason score (≤7) PCa, especially in delaying the disease progression. More studies with larger sample size and comprehensive study design are still needed to verify our outcomes.
format Online
Article
Text
id pubmed-7271889
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-72718892020-06-15 Prostate cancer patients can benefit from 5-alpha-reductase inhibitor treatment: a meta-analysis Deng, Tuo Lin, Xueming Duan, Xiaolu He, Zihao Zhao, Zhijian Zeng, Guohua PeerJ Drugs and Devices BACKGROUND: The efficacy and safety of 5α-reductase inhibitors (5ARIs) in treating prostate cancer (PCa) have not been fully determined. We performed a meta-analysis to evaluate the effectiveness and safety of 5ARIs for PCa patients. METHODS: A comprehensive literature search of online databases was conducted to obtain comparative studies exploring the effectiveness and safety of 5ARIs in treating PCa up to October 2019. Summarized odds ratio s (OR s) or hazard ratio s (HR s) were calculated to compare the outcomes between 5ARI and control groups. Our meta-analysis was registered in PROSPERO under number CRD42018109809. RESULTS: A total of 2,277 patients from 10 studies were included. No significant difference was found in prostate-specific antigen progression between two groups (OR = 0.82, 95% CI [0.52–1.29], P = 0.40). However, 5ARI treatment significantly reduced the total progression of PCa (OR = 0.61, 95% CI [0.48–0.77], P < 0.0001), especially for patients with local (OR = 0.56, 95% CI [0.44–0.73], P < 0.00001) and low-Gleason score (≤7) PCa (OR = 0.63, 95% CI [0.48–0.84], P = 0.002). Additionally, 5ARIs also significantly prolonged the progression-free survival time (HR = 0.57, 95% CI [0.34–0.96], P = 0.04) for PCa patients. No significant difference was found in the occurrence of PCa recurrence, metastasis, biopsy reclassification, and side-effects between two groups. CONCLUSIONS: Our study suggests that 5ARI treatment can benefit patients with local and low Gleason score (≤7) PCa, especially in delaying the disease progression. More studies with larger sample size and comprehensive study design are still needed to verify our outcomes. PeerJ Inc. 2020-06-01 /pmc/articles/PMC7271889/ /pubmed/32547884 http://dx.doi.org/10.7717/peerj.9282 Text en © 2020 Deng et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Drugs and Devices
Deng, Tuo
Lin, Xueming
Duan, Xiaolu
He, Zihao
Zhao, Zhijian
Zeng, Guohua
Prostate cancer patients can benefit from 5-alpha-reductase inhibitor treatment: a meta-analysis
title Prostate cancer patients can benefit from 5-alpha-reductase inhibitor treatment: a meta-analysis
title_full Prostate cancer patients can benefit from 5-alpha-reductase inhibitor treatment: a meta-analysis
title_fullStr Prostate cancer patients can benefit from 5-alpha-reductase inhibitor treatment: a meta-analysis
title_full_unstemmed Prostate cancer patients can benefit from 5-alpha-reductase inhibitor treatment: a meta-analysis
title_short Prostate cancer patients can benefit from 5-alpha-reductase inhibitor treatment: a meta-analysis
title_sort prostate cancer patients can benefit from 5-alpha-reductase inhibitor treatment: a meta-analysis
topic Drugs and Devices
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271889/
https://www.ncbi.nlm.nih.gov/pubmed/32547884
http://dx.doi.org/10.7717/peerj.9282
work_keys_str_mv AT dengtuo prostatecancerpatientscanbenefitfrom5alphareductaseinhibitortreatmentametaanalysis
AT linxueming prostatecancerpatientscanbenefitfrom5alphareductaseinhibitortreatmentametaanalysis
AT duanxiaolu prostatecancerpatientscanbenefitfrom5alphareductaseinhibitortreatmentametaanalysis
AT hezihao prostatecancerpatientscanbenefitfrom5alphareductaseinhibitortreatmentametaanalysis
AT zhaozhijian prostatecancerpatientscanbenefitfrom5alphareductaseinhibitortreatmentametaanalysis
AT zengguohua prostatecancerpatientscanbenefitfrom5alphareductaseinhibitortreatmentametaanalysis